Figure 6
From: MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer
MiR-494 decreases cellular sensitivity to cisplatin through caspase-2 down-regulation in A549 cells. Western blots showing caspase-3/7/8, cleaved caspase-3/7/8 after transfection of miR-494, or siCASP2 in (a) A549 and (b) H460 cells treated with cisplatin (4 mg/L) for 24 hours. Cell viability in (c) A549 and (d) H460 cells transfected with miR-494, miR-494/pLVX-CASP2-puro, or respective controls treated with different concentrations of cisplatin for 24 hours were measured with CCK8 array. (e) Apoptosis rate was shown in A549 cells transfected with miR-494, siCASP2, miR-494/pLVX-CASP2-puro, or respective controls through flow cytometry after treatment with cisplatin (4 mg/L) for 24 hours. The apoptotic cells were measured through Annexin V-FITC and propidium iodide staining and analyzed with FACS. The percentage of Q2 and Q3 cells was measured as apoptosis rate. Data are presented as the ± SD of three independent experiments. *P < 0.05; **P < 0.01; ****P < 0.0001.
